Life Long Learning Knowledge Assessment Course: Upper Tract Tumors/Urinary Diversion Webcast (2018)

This activity was taken from the 2017 Recertification (MOC) Review Course Webcast: Oncology and Urinary Diversion. The purpose of the AUA Recertification (MOC) Review Course is to prepare attendees for the ABU Recertification Examination. This course will be practice focused and will offer practical and clinically specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the Recertification Exam. Sample multiple choice practice questions as well as case based discussions and debates will be utilized to prepare attendees for the upcoming Recertification Examination.

Target Audience

This program is designed for:

  • Practicing urologists preparing for the Recertification (MOC) Examination.

Learning Objectives

Upon completion of this course, participants will be able to:

  1. Discuss the appropriate indications for and use diagnostic tests in the management of urologic cancers.
  2. Enhance ability to make guideline-based decisions regarding management of common urologic cancers.
  3. Recognize and execute appropriate measures to prevent and manage complications resulting for management intervention for urologic cancers.
  4. Develop and employ a disease stage appropriate surveillance schedule during post management follow-up of urologic cancers.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Course opens: 
Course expires: 

Faculty Disclosures
Sia Daneshmand, MD
: Endo: Meeting Participant or Lecturer; Cubist: Meeting Participant or Lecturer; Photocure: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Taris: Consultant or Advisor; Pacific Edge: Consultant or Advisor
Planner Disclosures
Education Council
Timothy Charles Brand, M.D.: 
Nothing to disclose
Anthony A. Caldamone MD: Nothing to disclose
Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
Matthew S. Christman, MD: Nothing to disclose                
Jody Donaldson: 
Nothing to disclose
Shelby Englert: Nothing to disclose
Matthew Thomas Gettman, MD: COVR Medical: Consultant or Advisor; Intuitive Surgical: Consultant or Advisor; Exact Sciences: Scientific Study or Trial
Inderbir Singh Gill ,MD, M.Ch.: Nothing to disclose
Howard B. Goldman, MD: allergan: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial: Cook: Scientific Study or Trial; Nuvectra: Consultant or Advisor; Axonics: Consultant or Advisor; NewUeo: Consultant or Advisor
William C. Huang, MD: Photocure: Scientific Study or Trial; Karl Storz: Scientific Study or Trial
William C. Hulbert Jr., MD: Nothing to disclose
Brant Inman, MD, MS, FRCSC: Dendreon: Scientific Study or Trial; Genentech Inc: Scientific Study or Trial; Combat Medical: Consultant or Advisor, Scientific Study or Trial; FKD Therapies: Scientific Study or Trial; Nucleix: Scientific Study or Trial; Urogen: Scientific Study or Trial
Mark L. Jordan, MD,FACS: Nothing to disclose
Hari K. Koul, MSC,PHD: Novartis Pharmaceuticals: Consultant or Advisor; Urologic Research: Leadership Position; PLOS one: Leadership Position; OMICS group: Leadership Position; Open Access Publishing: Leadership Position, Health Publishing
Martin A. Koyle, MD: Nothing to disclose
Yair Lotan ,MD: abbott: Scientific Study or Trial; Cepheid: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor, Scientific Study or Trial; biocancell: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Consultant or Advisor, Scientific Study or Trial
Nicole Lara Miller ,MD: Boston Scientific Corporation: Consultant or Advisor, Meeting Participant or Lecturer; Practical Reviews In Urology: Health Publishing
Manoj Monga, MD, FACS: Fortec: Other
Victor William Nitti, MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Medtronic: Scientific Study or Trial
Christopher Porter, MD: Nothing to disclose
Ganesh V. Raj, MD, PhD: Ptares: Owner, Product Development; C-diagnostics corp: Consultant or Advisor, Investment Interest; amgen: Meeting Participant or Lecturer; Johnson and Johnson: Consultant or Advisor, Owner, Product Development; Astellas: Meeting Participant or Lecturer; ASTELLAS: Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Owner, Product Development; BAYER: Consultant or Advisor, Meeting Participant or Lecturer; SANOFI: Consultant or Advisor, Meeting Participant or Lecturer; GaudiumRx: Leadership Position, Investment Interest, Owner, Product Development; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; EtiraRx: Leadership Position, Investment Interest, Owner, Product Development
Jay D. Raman, MD: American Kidney Stone Management: Investment Interest; Pacific Edge Biotechnology: Consultant or Advisor, Scientific Study or Trial
Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
Karl-Dietrich Sievert: AMS: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer; Stimguard: Meeting Participant or Lecturer, Scientific Study or Trial
Joseph A. Smith Jr., MD: Nothing to disclose
Ryan Patrick Terlecki, MD, FACS: American Medical Systems: Consultant or Advisor, Other; Allergan: Scientific Study or Trial
Edouard John Trabulsi, MD, FACS: GenomeDx: Consultant or Advisor

Method of Participation
To claim CME credit/hours of participation, the learner must complete to pre-test, view the webcast, complete the posttest passing with 80% accuracy and submit the evaluation.
Estimated time to complete this activity: 0.50 hours
Release Date: January, 2018
Expiration Date: January, 2021

Accreditation Statement
The Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians accredits the American Urological Association (AUA).
Credit Designation
The American Urological Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

AUA Privacy and Confidentiality Policy
Contact Information
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
CME Information

For all inquiries regarding CME credit email:

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation


Please login or register to take this course.